Weekly Recap | Zoetis -0.49%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.The Week
Zoetis (ZTS) fell 0.49% this week to close at $71.05, while the S&P 500 rose 1.21%, putting the stock about 1.7 percentage points behind the benchmark. The week ran up then faded: Monday (Sep 21) opened at $72.06, Tuesday (Sep 22) pushed to $72.86 before pulling back, Wednesday (Sep 23) touched a high of $73.55, then the final two sessions softened. Friday (Sep 25) dipped to $69.52 before ending at $71.05. Weekly amplitude was 5.59%, and the latest quote sits just above the close.
Key Events
Position updates and the Q3 earnings schedule dominated the headlines. On Monday (Sep 21), Nykredit established a new holding; on Tuesday (Sep 22), a note asked whether Zoetis was still 23% below fair value. Thursday (Sep 24) brought a flash that the stock outperformed competitors despite losing ground on the day, and the company confirmed it will host its fiscal Q3 2026 webcast and call on 5 November before the open. The week’s narrative centred on positioning shifts ahead of the next earnings report.
Analyst Ratings
Across 17 brokers covering Zoetis, 4 rate it buy, 4 overweight, and 9 hold, with no underweight or sell ratings. Consensus is buy, with a target of $96, or 35.12% above the latest price. Targets range from $80 to $155, a wide spread. Within the pharma industry, Zoetis ranks 10th out of 203 names.
The Week Ahead
The macro calendar is dense next week: Tuesday (Sep 29) includes JOLTS job openings, consumer confidence, FHFA home prices and the Case Shiller 20-city index. For Zoetis itself, the key date is 5 November pre-market results, with consensus EPS of $1.41 and revenue of $2.298 billion. Next week’s action likely tracks macro prints and animal-health peers rather than company news.
In Short
Zoetis lagged the market this week, trading between $69.52 and $73.55 and closing at $71.05. The sell-side leans positive: consensus is buy and the target sits 35% above spot, though the $80–$155 range signals wide disagreement. Valuation shows an 11.13x P/E and 9.33x P/B, and the latest session’s large- and medium-lot flows both pointed net buying, as did retail. The tension now sits on whether Q3 results can validate current expectations and how macro data shifts risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.